# Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

> **NCT00181584** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 60 (actual)

## Conditions studied

- Bone Loss
- Prostate Cancer

## Interventions

- **DRUG:** Zoledronic acid
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00181584
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2006-02
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00181584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00181584, "Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00181584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*